Conference Call with Syngene International Management and Analysts on Q3FY25 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Syngene International announced Q3FY25 results Reported revenue from operations up by 11% to Rs 944 crore. Reported PAT (after exceptional items) up by 18% to Rs 131 crore. Jonathan Hunt, Managing Director and Chief Executive Officer, Syngene International, said: “Syngene’s third quarter performance saw a return to growth across all business divisions that sets us up well for the next quarter. Our Discovery Services division saw the initial “China+1” pilot projects, with large and midsize pharma companies, starting to convert into longer term contracts. This underscores Syngene’s ability to build strong partnerships through a combination of great science and high operating and quality standards. Now, our focus is on further business development and building the sales pipeline. The quarter also saw positive momentum in our CDMO division led by biologics. Growth in the quarter suggests that market dynamics, particularly in US biotech, are stabilising, albeit later than expected.” Deepak Jain, Chief Financial Officer, Syngene International Limited said: “The third quarter performance delivered year-on-year growth. Reported profit after tax (before exceptional items) for the quarter grew by 14% supported by operating EBITDA margins that came in at 30.1%, up from 27.1% in the previous year. We continued to focus on investing in digital initiatives, new technologies and commercial capabilities to drive growth.” Result PDF
Conference Call with Syngene International Management and Analysts on Q2FY25 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Syngene International announced Q2FY25 results Revenue from operations increased sequentially by 13% QoQ to Rs 891 crore in Q2FY25, change -2% YoY compared to Rs 910 crore during Q2FY24. H1FY25 revenue was broadly flat, in line with our guidance, at Rs 1,681 crore change -2% YoY compared to Rs 1718 crore during H1FY24. EBITDA: Rs 261 crore compared to Rs 276 crore during Q2FY24 change -5%. PAT: Rs 106 crore compared to Rs 122 crore during Q2FY24 change -13%. Jonathan Hunt, Managing Director and Chief Executive Officer, Syngene International, said: “Performance in the second quarter and first half of the year was broadly flat, in line with our expectations. I am pleased with the early positive signs of recovery in Discovery Services, largely driven by collaborations on pilot projects with large and mid-sized biopharma clients looking for alternatives to China to rebalance their supply chains. I am also encouraged to see healthy interest from clients in biologics. We have proven capabilities in biologics and additional manufacturing capacity coming online in the second half of the year. With a strong third quarter already underway, we expect to see a positive change in revenue trajectory in the third quarter and remain on track to deliver within our guidance range for the full year.” Sibaji Biswas, Executive Director and Chief Financial Officer, Syngene International said: “With improving sequential revenues, our operating EBITDA margin came in at 27% for the quarter compared to 22% in the first quarter and broadly within range year-on-year. With recent investments in the research and CDMO businesses, we are in a good position to leverage opportunities to drive medium to long-term growth. The Company maintains a robust balance sheet with strong net cash position, enabling us to invest in strategic areas including digitization, commercial capabilities and new technology to support growth.” Result PDF